This federal contract award is for the delivery of RADIOPHARM, a nuclear medicine product, to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 15 (VISN 15). The contract was awarded on October 1, 2020 to Triad Isotopes, Inc., a for-profit pharmaceutical company that specializes in nuclear medicine. The potential value of the contract is $145,046.96, with a completion date of April 14, 2022. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation. Triad Isotopes has provided similar radiopharmaceuticals to other VISN networks under separate contract awards, supporting the VA's mission of providing nuclear medicine services to veterans.